H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on CytomX Therapeutics (CTMX) to $10 from $5 and keeps a Buy rating on the shares. The firm says “strong” CX-2051 trial demand and expansion of enrollment to 100 patients should provide a stronger signal for an approval path.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics price target raised to $6.50 from $5 at Piper Sandler
- CytomX Therapeutics Earnings Call Highlights Clinical Progress
- CytomX Therapeutics Reports Q3 2025 Financial Results
- CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
- CytomX Therapeutics Advances CX-2051 Study in Solid Tumors